Technical Analysis for YMAB - Y-mAbs Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 22.78 -0.83% -0.19
YMAB closed down 0.83 percent on Friday, July 19, 2019, on 34 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical YMAB trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Overbought Stochastic Strength 0.00%
Stochastic Sell Signal Bearish -0.83%
200 DMA Support Bullish -0.83%
20 DMA Support Bullish -0.83%
Hammer Candlestick Bullish -0.83%

Older signals for YMAB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Biopharmaceutical Cancer Cancer Treatment Brain Tumor Neuroblastoma Glioma Diffuse Intrinsic Pontine Glioma Refractory
Is YMAB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.0
52 Week Low 15.17
Average Volume 175,323
200-Day Moving Average 22.625
50-Day Moving Average 21.885
20-Day Moving Average 22.5975
10-Day Moving Average 22.852
Average True Range 0.8855
ADX 14.73
+DI 13.0593
-DI 20.4856
Chandelier Exit (Long, 3 ATRs ) 20.4935
Chandelier Exit (Short, 3 ATRs ) 23.9165
Upper Bollinger Band 23.4386
Lower Bollinger Band 21.7564
Percent B (%b) 0.61
BandWidth 7.444186
MACD Line 0.2474
MACD Signal Line 0.2381
MACD Histogram 0.0093
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.39
Resistance 3 (R3) 23.43 23.26 23.29
Resistance 2 (R2) 23.26 23.11 23.24 23.25
Resistance 1 (R1) 23.02 23.01 23.14 22.98 23.22
Pivot Point 22.86 22.86 22.92 22.84 22.86
Support 1 (S1) 22.62 22.70 22.74 22.58 22.34
Support 2 (S2) 22.45 22.61 22.43 22.31
Support 3 (S3) 22.21 22.45 22.27
Support 4 (S4) 22.17